As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on ...

India's benchmark indexes opened lower on Thursday after U.S. President Donald Trump slapped 26% reciprocal tariffs on ...

US President Donald Trump’s 26% reciprocal tariff on India is expected to have the greatest impact on the automotive, IT, and ...

The exemption given to Indian pharmaceuticals is positive and, therefore, this segment is likely to witness buying, says ...

The delisting action was determined after Virpax Pharmaceuticals failed to regain compliance with Nasdaq Listing Rule 5550 (b) (1). The delisting process will conclude with the filing of a Form 25 ...

President Trump's new tariffs send shockwaves through U.S. markets as a trade war unfolds. Follow along for live updates on ...

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable ...

European shares fell on Wednesday, weighed by losses in healthcare stocks, as investors awaited tariff plans from U.S.

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Learn more ...

Futures for the S&P 500 slumped 3.4% before the bell, while Dow Jones Industrial Average futures lost 2.8%, auguring ...

Former President Donald Trump unveiled sweeping new tariffs as he continues to move ahead with his domestic and foreign policy agenda. Follow here for the latest live news updates.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.